Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2004

View Archived Issues

Exelixis makes significant progress in expanding and advancing development pipeline during Q1

Nuvelo expands pipeline to three cardiovascular candidates

Nektar Therapeutics reports positive developments on late-stage programs

Effective wound healing by topical application of novel preclinical therapeutic peptides

Leptin accelerates wound angiogenesis in vivo

Latest phase III data on exenatide in type 2 diabetes presented at ADA

Tripep receives approval to conduct alphaHGA microdosing study

Wyeth reviews R&D pipeline

MDI-based insulin regimen is more cost-effective than CSII

Successful islet cell transplantation using the Edmonton protocol

CV Therapeutics and FDA agree on Ranexa study protocol

Positive phase III results for Aryplase in MPS VI

Solvay reviews bifeprunox development

V.I. Technologies to merge with Panacos

New phase II study of ABT-874 for MS

Iconix to provide advanced chemogenomic profiling services to AstraZeneca

Data on intratumoral injection of INGN-241 in advanced cancer patients

Trillium Therapeutics inlicenses cytokine receptor antagonist program

Enrollment completed in CONFIRM 1 study of PTK/ZK for colorectal cancer

Clofarabine NDA accepted for priority review

Strattera receives U.K. approval

LL-37 demonstrates angiogenic activity in vitro

Cannabinoid receptor partial agonist with antihyperalgesic and antiallodynic effects in vivo

SD-208 shows promise in models of pulmonary fibrosis

Losartan reduces lung injury in preclinical studies

Gilead claims new HIV integrase inhibitors

New bone resorption inhibitors targeting OCIF presented by Sankyo

Novel GAL3 antagonists and their use in depression and anxiety treatment

New hypoglycemic agents developed by Yissum and Hadasit researchers

Sumitomo patent covers novel agents for use in autoimmune diseases

New dopaminergic and serotonergic agents identified at ProteoSys

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...